Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Brock N, Hilgard P, Peukert M, et al: Basis and new developments in the field of oxazaphosphorines. Cancer Invest 6: 513–532, 1988.
Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.
Krämer I: Zehn Jahre Dokumentation von Zytostatika-Paravasat-Ereignissen: Auswertung von 175 Paravasate-Dokumentationen. Krankenhauspharmazie 23: 269–274, 2002.
Secondary literature
Summary of product characteristics Endoxan® (Germany), -Baxter, January 2002.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Donislawski S, Gain M, Meyer-Jürshof A, et al: Cyclophosphamid: Behandlung von Paravasaten. In: Donislawski S, et al (eds) -ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 2: 39, 1994.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Dorr RT, Von Hoff DD: Drug monographs: cyclophosphamide. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 319–332, 1994.
Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Summary of product characteristics Endoxan “Baxter” (Austria), Baxter, January 2002.
Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Cyclophosphamide. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_22
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)